Desoxypipradrol
Desoxypipradrol — also known as 2-DPMP, sold as "Ivory Wave" — is a synthetic stimulant of the piperidine class. It is a close structural relative of methylphenidate, but lasts dramatically longer. It blocks dopamine and norepinephrine clearance in the brain, causing forceful, sustained stimulation.
Desoxypipradrol (2-benzhydrylpiperidine) — also known as 2-DPMP — is a synthetic stimulant of the piperidine class. It is a close structural relative of methylphenidate, distinguished by an extraordinarily prolonged duration of action. Desoxypipradrol is a dopamine–norepinephrine reuptake inhibitor, producing its effects by blocking the clearance of these neurotransmitters from the synapse without triggering their release.[1]
Synthesized by CIBA in the 1950s alongside Methylphenidate, it was patented as a narcolepsy treatment but abandoned before human trials. It resurfaced around 2007 on research chemical markets as "Ivory Wave," and by 2010 had caused severe emergency presentations in Edinburgh and three reported deaths. It is now controlled in the UK, Germany, Finland, Sweden, and China, with no approved medical use.
Subjective effects include wakefulness, appetite suppression, mood elevation, cognitive drive, agitation, and paranoia. The experience is defined by its relentlessness — early clarity gives way to a grinding stimulation that resists sleep for one to three days. Anxiety, hallucinations, and compulsive redosing are characteristic unwanted effects; the slow onset frequently tricks users into redosing before the initial dose peaks.
Desoxypipradrol carries high abuse liability and severe acute toxicity — muscle breakdown occurred in 96% of one emergency case series,[1] and deaths have been reported. The extraordinary duration amplifies every risk: a single dose sustains cardiovascular overload for days, and no antidote exists.[2] No clinical trials have been conducted; all evidence comes from in vitro studies, animal models, and emergency case reports.[3]
History[edit]
Discovery
CIBA synthesized desoxypipradrol in the 1950s during the same piperidine research program that produced methylphenidate.[2] Patented in 1958 as a narcolepsy treatment, it was abandoned before human trials when methylphenidate proved clinically superior.
Emergence as a novel psychoactive substance
It resurfaced on research chemical markets around 2007 as 2-DPMP,[2] then surged in popularity in 2009–2010 under the brand "Ivory Wave" — a name previously used for mephedrone, creating dangerous confusion about the product's contents.[2][1] In summer 2010, 34 emergency department presentations in Edinburgh were linked to the compound, with muscle breakdown in 96% of cases and three reported deaths.[1]
Prohibition
The UK Advisory Council on the Misuse of Drugs recommended immediate action following the Edinburgh cluster.[4] An import ban took effect in November 2010, and desoxypipradrol was formally classified as Class B, Schedule 1 on 13 June 2012.[2] Finland, Sweden, Germany, and China added their own controls between 2012 and 2015.[5]
The name "desoxypipradrol" follows standard pharmaceutical nomenclature: "desoxy" (without oxygen) indicates the removal of the hydroxyl group present in the parent compound pipradrol. The abbreviation 2-DPMP (2-diphenylmethylpiperidine) became the standard designation in forensic and regulatory literature.
Chemistry[edit]
Structure
Desoxypipradrol belongs to the piperidine class — a family built around a six-membered nitrogen-containing ring.[2] Its molecular formula is C₁₈H₂₁N (molecular weight 251.4 g/mol). The molecule carries two unsubstituted phenyl rings at the 2-position of the piperidine ring, and unlike its relatives pipradrol and methylphenidate, it lacks polar functional groups entirely.[2] That absence makes the molecule highly fat-soluble, believed to explain its extraordinary duration.[6]
Desoxypipradrol, pipradrol, and Methylphenidate form a structural family from CIBA's 1950s piperidine research.[2] Functionally, it is grouped alongside compounds such as MDPV as a selective blocker of dopamine and norepinephrine reuptake, though the two classes are structurally unrelated.[7][8]
Pharmacology[edit]
Mechanism of action
Desoxypipradrol blocks the DAT and the NET, preventing these neurotransmitters from being cleared from the brain.[3] It does not trigger release of stored dopamine or norepinephrine — the mechanism is blocking reuptake, like cocaine, rather than forcing release, like amphetamine.[9] It has no meaningful activity at serotonin systems or dopamine receptors.[3]
Desoxypipradrol also lacks activity at a receptor (TAAR1) that normally acts as a brake on dopamine accumulation.[3] Without that brake, dopamine can build up without a natural ceiling — contributing to high abuse potential. At the dopamine transporter, it is roughly ten times more potent than cocaine.[3]
Pharmacokinetics
No human pharmacokinetic studies exist. Clinical cases show effects lasting one to three days, with psychiatric symptoms persisting longer[1] — one case lasted seven days, with the compound still detectable in blood at day four.[10] The prolonged duration reflects the molecule's fat-solubility and resistance to metabolism.[6] No half-life or metabolic pathway has been established. safety citation needed
Neuroscience[edit]
Where it acts
In the brain's reward center (the nucleus accumbens), desoxypipradrol produces a seven-fold spike in peak dopamine and extends the time dopamine lingers by fifteen-fold — substantially more than cocaine at comparable concentrations.[11] This sustained dopamine surge drives the compound's reinforcing properties, confirmed in animal self-administration studies.[12]
In the prefrontal cortex, it also elevates norepinephrine signaling, contributing to wakefulness and focus — but at higher exposures, to agitation and cognitive breakdown. The transporter blockade persists for days, which likely explains the multi-day psychosis and sustained sleeplessness documented in clinical cases.[1]
Why it matters
Dopamine is better understood as a signal for "wanting" — motivational drive — than for pleasure itself. As a pure dopamine reuptake inhibitor, desoxypipradrol powerfully amplifies compulsive craving and approach behavior while delivering comparatively limited hedonic reward. This mismatch likely explains why users report compulsive redosing despite limited euphoria.
The actual half-life in humans has never been measured — the multi-day symptom courses could reflect slow metabolism, slow transporter dissociation, redistribution from fat stores, or some combination.
Subjective Effects[edit]
The desoxypipradrol experience is less a discrete event than an occupation. Early hours bring wakefulness and cognitive drive. As the episode extends into its second and third day, the character shifts: clarity gives way to restless agitation, paranoid thinking, and perceptual disturbances. The slow onset frequently deceives users into redosing before effects peak.
The closest comparison is a prolonged methamphetamine binge compressed into a single dose, though without serotonergic activity desoxypipradrol has a harder, more purely driven quality. Relative to cocaine, the stimulation is comparable in intensity but lasts fifty to one hundred times longer — a pharmacokinetic profile with no close parallel among common stimulants.
Synthesized by CIBA in the 1950s alongside methylphenidate, desoxypipradrol was patented in 1958 as a candidate narcolepsy treatment but abandoned before clinical trials.[2] The compound resurfaced around 2007 on novel psychoactive substance markets, sold primarily as "Ivory Wave," and triggered a cluster of severe emergency presentations in Edinburgh in 2010.[3] It is now controlled in the United Kingdom, Germany, Finland, Sweden, and China, and remains absent from legitimate medical use.
Subjective effects include sustained wakefulness, appetite suppression, cognitive stimulation, and mood elevation. The experience is defined by its relentless persistence — a forceful, grinding stimulation that resists sleep for one to three days, with early-phase clarity giving way to agitation and paranoid ideation as the episode extends. Anxiety, perceptual disturbances, and compulsive redosing are characteristic unsought effects.
Desoxypipradrol carries high predicted abuse liability and severe acute toxicity — muscle breakdown occurred in 96% of one emergency case series.[3] The compound's extraordinary duration means a single dose can sustain sympathetic overload for days, compounded by the absence of any known antidote or reversal agent.[2] No clinical trials have been conducted; the evidence base rests entirely on in vitro pharmacology, animal models, case reports, and forensic toxicology.[1]
History[edit]
Discovery
Desoxypipradrol was synthesized by CIBA (now Novartis) during the 1950s as part of the same piperidine research program that produced pipradrol and methylphenidate.[2] The dehydroxylated structural analog of pipradrol, it was patented in 1958 as a candidate treatment for narcolepsy. Methylphenidate's shorter duration and more manageable pharmacokinetics proved clinically superior, and desoxypipradrol was abandoned without advancing to human trials.[2]
Emergence as a novel psychoactive substance
After decades of obscurity, desoxypipradrol appeared on research chemical markets around March 2007 under the name 2-DPMP.[2] Popularity surged in the United Kingdom during 2009–2010, primarily through a branded product called "Ivory Wave" — a name previously associated with mephedrone, causing widespread confusion about the active ingredient.[2][3]
In summer 2010, 34 emergency department presentations in Edinburgh were linked to the compound, with exceptionally severe clinical findings including muscle breakdown in 96% of cases and psychosis lasting days.[3] Three deaths were reported in August 2010 — believed to be the first fatalities attributable to the compound.[2]
Prohibition
The UK Advisory Council on the Misuse of Drugs recommended immediate action following the Edinburgh cluster and reported fatalities.[4] An import ban took effect in November 2010, and desoxypipradrol was formally classified as a Class B, Schedule 1 substance on 13 June 2012.[2] Finland, Sweden, Germany, and China followed with their own controls between 2012 and 2015, and the EMCDDA Early Warning System issued alerts across Europe.[5]
The name "desoxypipradrol" follows standard pharmaceutical nomenclature: "desoxy" (without oxygen) indicates the removal of the hydroxyl group present in the parent compound pipradrol. The abbreviation 2-DPMP (2-diphenylmethylpiperidine) became the standard designation in forensic and regulatory literature.
Chemistry[edit]
Structure
Desoxypipradrol consists of a six-membered piperidine ring bearing a diphenylmethyl (benzhydryl) group at the 2-position. Both phenyl rings are unsubstituted, and the piperidine nitrogen is secondary. The molecule lacks polar functional groups — specifically, it is missing the hydroxyl group present in its parent compound pipradrol and the ester group found in methylphenidate.[2]
This absence of easily metabolized groups contributes to high lipophilicity and is believed to underlie the compound's exceptionally prolonged duration of action.[6]
| Molecular formula | C₁₈H₂₁N |
| Molecular weight | 251.4 g/mol |
Stereochemistry
A single chirality centre at C-2 of the piperidine ring gives rise to two enantiomers. Material found on research chemical markets is the racemic mixture. The (R)-(−) enantiomer is the more pharmacologically active form at the DAT.[6]
The active enantiomers of desoxypipradrol and pipradrol are stereochemically superimposable on each other but not on the active enantiomer of amphetamine, indicating a distinct binding geometry at the transporter.[6]
Structure–activity relationships
Desoxypipradrol, pipradrol, and Methylphenidate form a structural family originating from CIBA's 1950s piperidine program.[2] Removing the hydroxyl group from pipradrol (yielding desoxypipradrol) dramatically increases lipophilicity and extends duration of action while maintaining comparable transporter potency.
Within novel psychoactive substance classification, desoxypipradrol is grouped functionally alongside pyrovalerone cathinones such as MDPV as a selective catecholamine reuptake inhibitor, though the two classes are structurally unrelated.[7][8]
Pharmacology[edit]
Mechanism of action
Desoxypipradrol blocks the DAT (DAT) and NET (NET), preventing the reuptake of these neurotransmitters from the synapse.[1] It has no meaningful activity at the SERT and does not cause the release of stored monoamines — making its mechanism cocaine-like (blocking reuptake) rather than amphetamine-like (forcing release).[9]
At the dopamine transporter, desoxypipradrol is comparable in potency to methylphenidate and roughly ten times more potent than cocaine.[1] It shows no binding at serotonin receptors, dopamine receptors, adrenergic receptors, or TAAR1 (TAAR1).[1]
The absence of TAAR1 activity is significant: this receptor normally acts as a brake on dopaminergic signaling, and compounds that activate it tend to have lower abuse potential. Its absence from desoxypipradrol's profile removes a natural ceiling on dopamine accumulation.[1]
Molecular modeling confirms that desoxypipradrol locks the dopamine transporter in an outward-facing conformation — the same mechanism cocaine uses, and distinct from the transporter-reversing action of amphetamines.[9] Studies using mutant transporters further confirm a cocaine-type binding profile.[10]
Pharmacokinetics
No formal human pharmacokinetic studies have been published. The compound's defining pharmacokinetic feature is its extraordinary duration — clinical presentations consistently involve multi-day symptom courses, with psychiatric effects persisting for days after a single dose.[3]
One case report documented a seven-day symptom course following a large overdose, with the compound still detectable in blood at day four.[11] A Finnish study of 106 drivers who tested positive for 2-DPMP found a wide range of blood concentrations, with post-mortem cases showing higher levels.[12]
The prolonged duration is attributed to the molecule's high lipophilicity and absence of easily metabolized functional groups.[6] No half-life has been formally determined, and no metabolic pathway or enzyme involvement has been identified — a critical knowledge gap given the compound's documented severity of harm. safety citation needed
Neuroscience[edit]
Where it acts
Desoxypipradrol potentiates dopamine and norepinephrine signaling across multiple brain circuits. In the nucleus accumbens — the core reward region — it produces a seven-fold increase in peak dopamine levels and a fifteen-fold prolongation of dopamine clearance time, substantially exceeding cocaine's effects at comparable concentrations.[13] This sustained dopamine accumulation in reward circuitry drives the compound's reinforcing properties, confirmed by animal self-administration studies.[14]
In the prefrontal cortex, norepinephrine reuptake blockade enhances both noradrenergic and dopaminergic tone, contributing to wakefulness, focus, and — at higher exposures — agitation and cognitive disorganization. The extremely prolonged transporter occupancy means these circuits remain potentiated for days, potentially explaining the multi-day psychosis and sustained insomnia documented in clinical cases.[3]
Why it matters
The incentive salience model distinguishes between dopamine-mediated "wanting" (motivational drive) and "liking" (hedonic pleasure). As a pure dopamine reuptake inhibitor with no serotonergic or opioidergic activity, desoxypipradrol is predicted to powerfully amplify compulsive wanting — approach behavior, craving, motivational urgency — while providing comparatively limited hedonic reward. This dissociation may explain why users report compulsive redosing despite limited euphoria.
Several fundamental questions remain unanswered. The actual half-life in humans has never been measured — the multi-day symptom courses could reflect slow metabolism, slow dissociation from the transporter, redistribution from fat stores, or some combination.
Subjective Effects[edit]
The desoxypipradrol experience is less a discrete event than an occupation. Early hours bring forceful cognitive clarity, elevated motivation, and confident wakefulness — a recognizable stimulant state. As the episode extends into its second and third day, the character shifts: clarity gives way to restless agitation, perceptual disturbances creep in, and paranoid ideation can take hold as pharmacological stimulation compounds mounting sleep deprivation. The slow oral onset frequently deceives users into redosing before effects manifest, compounding the problem.
The closest experiential comparison is a prolonged methamphetamine binge compressed into a single dose, though the absence of serotonergic activity gives desoxypipradrol a harder, more purely driven quality. Relative to cocaine, the stimulation is comparable in intensity but persists fifty to one hundred times longer — a pharmacokinetic profile with no close parallel among common stimulants.
Effect Grid
Pronounced, sustained stimulation with forceful wakefulness lasting 24 hours or longer from a single dose. Focus enhancement and motivation are prominent in the early phase, accompanied by significant thought acceleration and appetite suppression. Cognitive effects shift over time — initial clarity and thought organization give way to restlessness and emerging irritability as the experience extends past 12 hours.
Sympathomimetic activation is significant: tachycardia, vasoconstriction, bruxism, and excessive sweating are expected. Spontaneous body sensations and dehydration sensation are common. The risk of compulsive redosing increases as users seek to recapture early-phase cognitive clarity.
Insomnia is near-certain for 24–48 hours. Appetite suppression is pronounced. The extremely slow onset (1–4 hours oral) makes redosing before effects fully manifest a critical danger — cumulative dosing is the primary overdose pathway documented in case literature.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Auditory hallucinations · External hallucinations · Shadow people
Appetite suppression · Restlessness · Dry mouth · Pupil dilation · Muscle tension · Heart rate perception changes · Excessive sweating · Dehydration sensation · Body high · Spontaneous body sensations · Tingling / electric sensations · Bruxism · Trembling · Nausea · Headache · Respiratory stimulation · Bodily lightness · Motor control enhancement · Vibrations / buzzing · Dizziness · Constipation · Tactile euphoria · Sexual arousal enhancement · Sexual arousal suppression · Vomiting · Involuntary body movements · Tactile hallucination
Muscle tension · Heart rate perception changes · Excessive sweating · Dehydration sensation · Body high · Spontaneous body sensations · Tingling / electric sensations · Bruxism · Trembling · Nausea · Headache · Respiratory stimulation · Bodily lightness · Motor control enhancement · Vibrations / buzzing · Dizziness · Constipation · Tactile euphoria · Sexual arousal enhancement · Sexual arousal suppression · Vomiting · Involuntary body movements · Tactile hallucination
Cognitive euphoria · Cognitive dysphoria · Motivation suppression · Focus enhancement · Memory fragmentation · Multiple thought streams · Information processing enhancement · Analysis enhancement · Cognitive impairment · Confusion · Focus suppression · Thought disorganization · Thought loops · Analysis suppression · Delusions · Delirium
Focus enhancement · Memory fragmentation · Multiple thought streams · Information processing enhancement · Analysis enhancement · Cognitive impairment · Confusion · Focus suppression · Thought disorganization · Thought loops · Analysis suppression · Delirium
Irritability · Dysphoria · Emotional lability · Mania
Sociability enhancement · Communication enhancement · Sociability suppression · Communication suppression · Depersonalization · Derealization · Social disconnection
Depersonalization · Derealization · Social disconnection
Timeline
Gradual, insidious onset of stimulation; often imperceptible for the first 1–2 hours. Subtle increase in alertness may be the only sign.
Progressive build of stimulation, wakefulness, and appetite suppression. Focus enhancement and thought acceleration become noticeable.
Maximal stimulation, focus, and sympathomimetic activation. At higher doses, agitation and perceptual disturbances emerge. Sleep is impossible.
Sustained stimulation with diminishing positive effects; increasing agitation, irritability, and paranoia as sleep deprivation accumulates. Thought disorganization replaces clarity.
Gradual decline in stimulation. Fatigue, dysphoria, and cognitive impairment emerge but residual wakefulness may persist.
Prolonged crash with fatigue, depression, hypersomnia, and anhedonia. Duration poorly characterized.
⚠ Do not drive for at least 72 hours after last dose — cognitive impairment and residual stimulation persist well beyond subjective offset.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- cocaine · methylphenidate · amphetamine
Toxicity
No controlled toxicity studies exist for desoxypipradrol. All toxicity data comes from emergency presentations and forensic cases.
Muscle breakdown
Muscle breakdown (rhabdomyolysis) occurred in 96% of the Edinburgh emergency case series[1] — an exceptional rate among stimulant intoxications. The mechanism isn't established, but likely reflects prolonged muscle tension from sustained stimulation combined with elevated body temperature.
Muscle breakdown releases proteins into the bloodstream that can cause acute kidney failure. This risk is amplified in anyone with pre-existing kidney problems.
Cardiovascular effects
Rapid heart rate was documented in 65% and rapid breathing in 76% of Edinburgh cases.[1] High blood pressure and vascular constriction are expected from norepinephrine buildup. The multi-day duration means cardiovascular stress is sustained far longer than with typical stimulants.
Fatalities
Three deaths were reported in the UK in August 2010.[2] Finnish forensic data identified desoxypipradrol in five autopsy cases, with the compound considered a contributing factor in two.[13] German forensic data found it alongside synthetic opioids in patients who died of respiratory failure.[14]
Polydrug use is consistently present in published post-mortem data — desoxypipradrol is rarely identified as the sole cause of death.[2][13]
Chronic toxicity
No formal chronic toxicity studies exist. Prolonged high-potency dopamine stimulation predicts cardiovascular, psychiatric, and kidney risks comparable to or exceeding those of cocaine and methamphetamine with repeated use. inferred
Psychological Risks
Prolonged psychosis is the most clinically significant psychiatric risk. Hallucinations occurred in 50% of Edinburgh cases, paranoia in 21%.[1] Unlike cocaine or amphetamine psychosis, which typically resolve within hours, desoxypipradrol-associated psychosis can persist three to seven days.[1][10]
Delirium and mania are documented features of severe intoxication.[8] The compound produces "states of psychosis, mania and addiction at a significantly higher rate than other stimulants".[15] No data on lasting psychological effects after use has been published.
Tolerance and Dependence
Animal models confirm reinforcing properties: mice develop conditioned place preference and maintain intravenous self-administration.[12] The pharmacological profile predicts high abuse liability: selective dopamine and norepinephrine reuptake inhibitor, ten times the potency of cocaine at the DAT, and greater magnitude and duration of dopamine accumulation.[3][11] Desoxypipradrol is classified among substances with the highest addiction potential, alongside MDPV and naphyrone.[7]
Withdrawal has not been formally studied. The stimulant crash typically brings low mood, fatigue, excessive sleep, and anhedonia — these are class-level predictions. inferred The prolonged duration suggests a potentially prolonged crash, but this has not been studied. safety citation needed
Drug Interactions
Serotonergic substances
Combining desoxypipradrol with serotonin-releasing substances such as MDMA or mephedrone can produce serotonin syndrome — a potentially life-threatening overheating and seizure response.[15] MDMA combination is classified as dangerous, with risks including serotonin syndrome, severe overheating, and cardiovascular crisis from additive stimulant load.[15]
Opioids
Desoxypipradrol was co-detected with synthetic opioids in comatose patients with respiratory failure.[14] The stimulant can mask opioid-induced breathing depression — and because desoxypipradrol lasts so long, it may outlast multiple opioid doses, with suppressed breathing only becoming apparent later.
Seizure-threshold substances
Tramadol combination is classified as potentially lethal. Tramadol lowers the seizure threshold while stimulant-induced neuronal excitation compounds the risk, with additional cardiovascular strain from combined effects. safety citation needed
Other stimulants
Co-use with amphetamine was documented in Finnish driving cases.[13] Any stimulant combination adds dopaminergic load, with particular risk of cardiovascular events and muscle breakdown.
Contraindications
6 knownNo substance-specific contraindication studies exist. The following are inferred from the pharmacological profile and documented clinical toxicity. inferred
Heart conditions: Absolute contraindication. Dopamine and norepinephrine buildup produces sustained increases in heart rate, blood pressure, and vascular constriction.
Psychotic spectrum disorders: Absolute contraindication. Desoxypipradrol produces psychosis in 50% of documented clinical cases at intoxicating doses.[1] Individuals with schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features face extreme risk.
Seizure disorders: Relative contraindication. Stimulant-induced neuronal excitability may lower the seizure threshold.
Kidney impairment: Relative contraindication given the 96% muscle breakdown rate.[1] Pre-existing kidney problems reduce the ability to clear the proteins released during muscle breakdown.
MAOIs: Absolute contraindication. Combining monoamine oxidase inhibitors with a potent catecholamine reuptake inhibitor risks dangerous blood pressure crisis. safety citation needed
Pregnancy and lactation: Absolute contraindication. No reproductive toxicology data exist. Sustained sympathetic stimulation poses risks to placental blood flow and fetal development. inferred
Harm Reduction[edit]
Forms & Identification
Desoxypipradrol has appeared on unregulated markets primarily as a powder or in branded products such as "Ivory Wave." The brand-name confusion is a specific hazard: "Ivory Wave" was previously associated with mephedrone, and the same label has appeared on packages containing entirely different active ingredients.[1]
Reagent testing can help exclude some substances but may not definitively confirm desoxypipradrol. Sending a sample to a drug checking service is the most reliable identification method available.
Guidelines
- Verify substance identity through a drug checking service before use — branded products and powder sold as "2-DPMP" have contained other active ingredients
- Start with the lowest reported active dose; the slow oral onset (one to four hours) makes premature redosing the single most common path to overdose with this compound
- Do not redose — the slow onset deceives users into thinking the initial dose was insufficient; the full effect may not manifest for hours
- Ensure continuous access to water — sustained stimulation and muscle tension increase dehydration risk and compound the muscle breakdown hazard
- Have benzodiazepines available (only if prescribed or legally accessible) — they are the first-line clinical treatment for stimulant agitation and may help manage the extended tail of the experience
- Do not use alone — psychosis risk increases substantially as the experience extends beyond 24 hours
- Avoid physical exertion during effects — muscle breakdown is the most common severe adverse effect
Set & Setting
The most important consideration with desoxypipradrol is duration. A single oral dose can sustain effects for 24–72 hours, committing to at least one — and potentially three — days of forced wakefulness and sympathetic arousal.
A sober, trusted companion who understands the expected duration is strongly advised, particularly given the compound's documented capacity to produce paranoia and perceptual disturbances as the experience extends.
Aftercare & integration. The primary recovery priorities after desoxypipradrol use are sleep, hydration, and nutrition. The body has been under sustained sympathetic stress for one to three days — recovery takes proportionally longer than after shorter-acting stimulants.
Sleep may remain difficult for 12–24 hours after effects begin to fade. A dark, quiet environment and avoiding further stimulants (including caffeine) supports natural sleep onset. Rebound hypersomnia — sleeping 12–20 hours — is expected and should not be interrupted.
Hydration and electrolyte replacement are critical, given the high muscle breakdown risk. Dark or brown urine after use warrants immediate medical evaluation even if the person otherwise feels recovered. Light, easily digestible food should be reintroduced gradually.
Recovery & Support
Desoxypipradrol's pharmacological profile — high DAT potency without a natural ceiling — predicts significant dependence risk with repeated use. Anyone finding it difficult to stop or experiencing compulsive redosing should seek support early.
Stimulant-specific recovery resources include SMART Recovery, which uses cognitive-behavioral approaches, and Crystal Meth Anonymous (which serves people using any stimulant, not only methamphetamine). Medical evaluation is recommended for anyone experiencing persistent low mood, anhedonia, or cognitive difficulties lasting more than two weeks after last use.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Dark or brown urine (sign of muscle breakdown and kidney stress)
- Chest pain or irregular heartbeat
- Body temperature hot to the touch through clothing
- Seizure or loss of consciousness
- Psychosis with self-harm risk or complete disconnection from reality
- Symptoms worsening beyond 48 hours rather than resolving
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Move the person to a cool, quiet environment
- 3. Offer water if they can swallow safely
- 4. Do not physically restrain unless there is immediate danger of self-harm — restraint can worsen muscle breakdown
- 5. Monitor breathing and consciousness continuously
- 6. If unconscious but breathing, place in the recovery position
What to tell the dispatcher: Name the substance (desoxypipradrol / 2-DPMP), estimated amount, time taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for desoxypipradrol. Clinical management is entirely supportive.
Legal Status[edit]
Desoxypipradrol was unregulated worldwide until 2010, when clinical emergencies and deaths in the United Kingdom triggered rapid regulatory action.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class B, Schedule 1 (Misuse of Drugs Act 1971) | Importation ban announced November 2010; formal ban November 2011. Reclassified from Class C to Class B on 13 June 2012. No recognised medical use. Production and supply also prohibited under Psychoactive Substances Act 2016.[2][4] |
| Germany | Anlage II BtMG (Narcotics Act, Schedule II) | Controlled since 13 December 2014. Manufacture, possession, import, export, and sale prohibited without licence.[6] |
| Finland | Controlled substance | Controlled since 2012. 2-DPMP features prominently in Finnish forensic and driving-under-the-influence toxicology studies.[13] |
| Sweden | Controlled substance | Controlled since 2012.[6] |
| China | Controlled substance | Listed as controlled since October 2015.[6] |
| United States | Not specifically scheduled | No DEA Schedule I–V listing confirmed. May be covered by the Federal Analogue Act (21 U.S.C. § 813) due to structural similarity to pipradrol (Schedule V) if intended for human consumption. citation needed |
| Canada | Not specifically scheduled | No listing confirmed under the Controlled Drugs and Substances Act. Analogue provisions may apply. citation needed |
| Australia | Not specifically scheduled | Structural similarity to pipradrol may trigger analogue provisions under state and territory legislation, but no specific scheduling confirmed. citation needed |
The EMCDDA Early Warning System issued alerts on desoxypipradrol in 2010, prompting regulatory responses across European jurisdictions.[5]
Legal status changes frequently and varies by jurisdiction. This information is not legal advice — verify current law before relying on it.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- cocaine · methylphenidate · amphetamine
Toxicity
No controlled toxicity studies or lethal dose determinations exist for desoxypipradrol in any species. All toxicity data derives from emergency presentations and forensic cases.
Muscle breakdown
Muscle breakdown (rhabdomyolysis) is the most distinctive acute toxicity finding, occurring in 96% of the 34-patient Edinburgh case series.[3] This rate is exceptional among stimulant intoxications. The mechanism is not established but likely involves some combination of prolonged muscle tension from sustained stimulation, elevated body temperature, and involuntary muscle contractions.
Muscle breakdown releases proteins into the bloodstream that can cause acute kidney failure. This risk is amplified in anyone with pre-existing kidney impairment.
Cardiovascular effects
Rapid heart rate was documented in 65% and rapid breathing in 76% of Edinburgh cases.[3] Elevated blood pressure and vasoconstriction are expected consequences of norepinephrine reuptake blockade. The multi-day duration of effects means cardiovascular stress is sustained far longer than with typical stimulants.
Fatalities
Three deaths in the UK were reported in August 2010.[2] Finnish forensic data identified the compound in five autopsy cases, with desoxypipradrol considered a contributing factor in two.[12] German forensic data co-detected the compound with synthetic opioids in patients who died of respiratory failure.[15]
In published post-mortem data, polydrug use is consistently present — desoxypipradrol is rarely identified as the sole cause of death.[2][12]
Chronic toxicity
No formal chronic toxicity studies exist. Prolonged high-potency dopamine stimulation predicts cardiovascular, psychiatric, and kidney risks comparable to or exceeding those of cocaine and methamphetamine with repeated use. inferred
Psychological Risks
Prolonged psychosis is the most clinically significant psychiatric feature. Hallucinations (auditory and visual) occurred in 50% of Edinburgh cases, paranoia in 21%.[3] The compound produces "states of psychosis, mania and addiction at a significantly higher rate than other stimulants".[16]
Unlike cocaine or amphetamine psychosis, which typically resolves within hours of cessation, desoxypipradrol-associated psychosis can persist for three to seven days.[3][11] This prolonged course creates management challenges: patients may require psychiatric observation for days and may present repeatedly to emergency services before symptoms resolve.
Delirium and mania are documented features of severe intoxication.[8] Sustained dopaminergic stimulation lasting days represents a potent trigger for psychotic episodes in predisposed individuals. inferred
No data on persistent psychological effects (lasting cognitive impairment, perceptual disturbances) following desoxypipradrol use have been published.
Tolerance and Dependence
No formal tolerance or dependence studies have been conducted in humans. Animal models confirm reinforcing properties: mice develop conditioned place preference and maintain intravenous self-administration.[14]
The pharmacological profile predicts high abuse liability based on converging indicators: highly selective dopamine/norepinephrine reuptake inhibitor, absence of TAAR1 activity (removing a natural brake on dopaminergic drive), ten-fold greater potency than cocaine at the DAT, and greater magnitude and duration of dopamine accumulation.[1][13] Desoxypipradrol is classified among substances with the highest addiction potential, alongside MDPV and naphyrone.[7]
No withdrawal characterization studies exist. Withdrawal from dopaminergic stimulants generally involves low mood, fatigue, excessive sleep, and anhedonia — these are class-level predictions. inferred The prolonged duration of action suggests a potentially prolonged crash period, but this has not been studied. safety citation needed
Drug Interactions
Serotonergic substances
Desoxypipradrol itself has no serotonin activity, but combining it with serotonin-releasing substances (MDMA, mephedrone) can produce serotonin syndrome through a compound mechanism.[16] MDMA combination is classified as dangerous — risks include serotonin syndrome, severe overheating, and cardiovascular crisis from additive stimulant load.[16]
Opioids
Desoxypipradrol was co-detected with synthetic opioids in comatose patients with respiratory failure.[15] The stimulant can mask opioid-induced breathing depression until it wears off — and desoxypipradrol's exceptional duration complicates this dynamic, potentially outlasting multiple opioid doses.
Seizure-threshold substances
Tramadol combination is classified as potentially lethal — tramadol lowers the seizure threshold while stimulant-induced neuronal excitability compounds the risk, with additional cardiovascular strain from combined effects. safety citation needed
Other stimulants
Co-use of desoxypipradrol with amphetamine was documented in Finnish driving-under-the-influence cases.[12] Additive dopaminergic toxicity is expected from any stimulant combination, with particular risk of cardiovascular events and muscle breakdown.
Contraindications
6 knownNo substance-specific contraindication studies exist. The following are inferred from the pharmacological mechanism and documented clinical toxicity. inferred
Heart conditions: Absolute contraindication. Dopamine and norepinephrine reuptake inhibition produces sustained increases in heart rate, blood pressure, and blood vessel constriction.
Psychotic spectrum disorders: Absolute contraindication. Desoxypipradrol produces psychosis in 50% of documented clinical cases at intoxicating doses.[3] Individuals with schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features face extreme risk.
Seizure disorders: Relative contraindication. Stimulant-induced neuronal excitability may lower the seizure threshold.
Kidney impairment: Relative contraindication given the 96% muscle breakdown rate.[3] Pre-existing kidney problems reduce the ability to clear the proteins released during muscle breakdown.
MAOIs: Absolute contraindication. Monoamine oxidase inhibitors combined with potent catecholamine reuptake inhibitors risk dangerous blood pressure crisis. safety citation needed
Pregnancy and lactation: Absolute contraindication. No reproductive toxicology data exist. Sustained sympathetic stimulation poses risks to placental blood flow and fetal development. inferred
Harm Reduction[edit]
Forms & Identification
Desoxypipradrol has appeared on unregulated markets primarily as a powder or in branded products such as "Ivory Wave." The brand-name confusion is a specific hazard: "Ivory Wave" was previously associated with mephedrone-containing products, and the same label has appeared on packages containing entirely different active ingredients.[3] Branded packaging should never be trusted as an indicator of contents.
Reagent testing can help exclude some substances but may not definitively confirm desoxypipradrol — sending a sample to a drug checking service is the most reliable identification method available.
Guidelines
- Verify substance identity through a drug checking service before use — branded products and powder sold as "2-DPMP" have contained other active ingredients
- Start with the lowest reported active dose; the slow oral onset (one to four hours) makes premature redosing the single most common path to overdose with this compound
- Do not redose — the slow onset deceives users into thinking the initial dose was insufficient; the full effect may not manifest for hours
- Ensure continuous access to water — sustained stimulation and muscle tension increase dehydration risk and compound the muscle breakdown hazard
- Have benzodiazepines available (only if prescribed or legally accessible) — they are the first-line clinical treatment for stimulant agitation and may help manage the extended tail of the experience
- Do not use alone — psychosis risk increases substantially as the experience extends beyond 24 hours
- Avoid physical exertion during effects — muscle breakdown is the most common severe adverse effect
Set & Setting
The most important consideration with desoxypipradrol is duration. A single oral dose can sustain effects for 24–72 hours, meaning any use commits the user to at least one full day — and potentially three — of forced wakefulness and sympathetic arousal. Use should only be considered when at least 72 hours of unscheduled time follows the dose, with a safe, comfortable environment available throughout.
A sober, trusted companion who understands the expected duration is strongly advised, particularly given the compound's documented capacity to produce paranoia and perceptual disturbances as the experience extends.
Aftercare & integration. The primary recovery priorities after desoxypipradrol use are sleep, hydration, and nutrition. The extended duration means the body has been under sustained sympathetic stress for one to three days — recovery takes proportionally longer than after shorter-acting stimulants.
Sleep may remain difficult for 12–24 hours after subjective effects begin to fade. A dark, quiet environment and avoidance of further stimulants (including caffeine) supports natural sleep onset. Rebound hypersomnia — sleeping for 12–20 hours — is expected and should not be interrupted.
Hydration and electrolyte replacement are critical, particularly given the high muscle breakdown risk. Dark or brown urine after use warrants immediate medical evaluation even if the person otherwise feels recovered. Light, easily digestible food should be reintroduced gradually.
Recovery & Support
Desoxypipradrol's pharmacological profile — high DAT potency without a natural ceiling mechanism — predicts significant dependence risk with repeated use. Anyone finding it difficult to stop using or experiencing compulsive redosing patterns should seek support early.
Stimulant-specific recovery resources include SMART Recovery, which uses cognitive-behavioral approaches, and mutual aid groups such as Crystal Meth Anonymous (which serves people using any stimulant, not only methamphetamine). Medical evaluation is recommended for anyone experiencing persistent low mood, anhedonia, or cognitive difficulties lasting more than two weeks after last use.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Dark or brown urine (sign of muscle breakdown and kidney stress)
- Chest pain or irregular heartbeat
- Body temperature hot to the touch through clothing
- Seizure or loss of consciousness
- Psychosis with self-harm risk or complete disconnection from reality
- Symptoms worsening beyond 48 hours rather than resolving
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Move the person to a cool, quiet environment
- 3. Offer water if they can swallow safely
- 4. Do not physically restrain unless there is immediate danger of self-harm — restraint can worsen muscle breakdown
- 5. Monitor breathing and consciousness continuously
- 6. If unconscious but breathing, place in the recovery position
What to tell the dispatcher: Name the substance (desoxypipradrol / 2-DPMP), estimated amount, time taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for desoxypipradrol. Clinical management is entirely supportive.
Legal Status[edit]
Desoxypipradrol was unregulated worldwide until 2010, when a series of clinical emergencies and deaths in the United Kingdom prompted rapid regulatory action. The compound is now specifically controlled in several jurisdictions, primarily in Europe and East Asia. In the United States, Canada, and Australia, desoxypipradrol is not specifically scheduled but may fall under structural analog provisions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class B, Schedule 1 (Misuse of Drugs Act 1971) | Importation ban announced November 2010; formal ban November 2011. Reclassified from Class C to Class B on 13 June 2012. No recognised medical use. Production and supply also prohibited under Psychoactive Substances Act 2016.[2][4] |
| Germany | Anlage II BtMG (Narcotics Act, Schedule II) | Controlled since 13 December 2014. Manufacture, possession, import, export, and sale prohibited without licence.[6] |
| Finland | Controlled substance | Controlled since 2012. 2-DPMP features prominently in Finnish forensic and driving-under-the-influence toxicology studies.[12] |
| Sweden | Controlled substance | Controlled since 2012.[6] |
| China | Controlled substance | Listed as controlled since October 2015.[6] |
| United States | Not specifically scheduled | No DEA Schedule I–V listing confirmed. May be covered by the Federal Analogue Act (21 U.S.C. § 813) due to structural similarity to pipradrol (Schedule V) if intended for human consumption. citation needed |
| Canada | Not specifically scheduled | No listing confirmed under the Controlled Drugs and Substances Act. Analogue provisions may apply. citation needed |
| Australia | Not specifically scheduled | Structural similarity to pipradrol may trigger analogue provisions under state and territory legislation, but no specific scheduling confirmed. citation needed |
The EMCDDA Early Warning System issued alerts on desoxypipradrol in 2010, prompting the regulatory responses across European jurisdictions.[5]
Frequently asked questions
What is Desoxypipradrol?
Desoxypipradrol is a piperidine-class stimulant and selective dopamine–norepinephrine reuptake inhibitor with an exceptionally long duration of action. Synthesized by CIBA in the 1950s and abandoned before clinical trials, it emerged on NPS markets around 2007.
How long does Desoxypipradrol last?
Total duration by route of administration — Oral: 16 – 72 hours; Insufflated: 10 – 72 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Desoxypipradrol?
Psychedex publishes a dosage table for Desoxypipradrol on this page covering these routes of administration: oral, insufflated. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Desoxypipradrol?
The highest-severity documented interactions for Desoxypipradrol: Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous), Anticholinergics (Dangerous), Antipsychotics (Dangerous), Caffeine (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Desoxypipradrol addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Desoxypipradrol: tolerance builds moderate; full reset takes 10.5 days; cross-tolerance develops with cocaine, methylphenidate, amphetamine. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcdefghijklmnMurray DB, Potts S, Haxton C, Jackson G, Sandilands EA, Ramsey J, Puchnarewicz M, Holt DW, Johnston A, Bateman DN, Dear JW (2012) 'Ivory wave' toxicity in recreational drug users; integration of clinical and poisons information services to manage legal high poisoning — Clinical Toxicology doi:10.3109/15563650.2011.647992
- [2] ^abcdefghijkCorkery JM, Elliott S, Schifano F, Corazza O, Ghodse AH (2012) 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): A preliminary review — Progress in Neuro-Psychopharmacology & Biological Psychiatry doi:10.1016/j.pnpbp.2012.05.021
- [3]
- [4]
- [5]
- [6]
references
- [1]
- [2] ^abcdefghijklmCorkery JM, Elliott S, Schifano F, Corazza O, Ghodse AH (2012) 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): A preliminary review — Progress in Neuro-Psychopharmacology & Biological Psychiatry doi:10.1016/j.pnpbp.2012.05.021
- [3] ^abcdefghijklmnoMurray DB, Potts S, Haxton C, Jackson G, Sandilands EA, Ramsey J, Puchnarewicz M, Holt DW, Johnston A, Bateman DN, Dear JW (2012) 'Ivory wave' toxicity in recreational drug users; integration of clinical and poisons information services to manage legal high poisoning — Clinical Toxicology doi:10.3109/15563650.2011.647992
- [4]
- [5]
- [6]